Search

Displaying results 5241 - 5250 of 10000 in total
  1. Drug

    OBE101

    go.drugbank.com/drugs/DB05080
    Experimental

    Obecure is repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of obese individuals and for other weight management indications. … OBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine.

  2. Drug

    D-Tryptophan

    go.drugbank.com/drugs/DB03225
    Experimental

    The distinguishing structural characteristic of tryptophan is that it contains an indole functional group. It is an essential amino acid as defined by its growth effects on rats. … Tryptophan is one of the 20 standard amino acids, as well as an essential amino acid in the human diet. It is encoded in the standard genetic code as the codon UGG.

  3. Drug

    HSV-2 theracine

    go.drugbank.com/drugs/DB05811
    Experimental

    HSV-2 theracine is an attenuated recombinant vaccine developed by AuRx for the treatment of genital herpes.

  4. Drug

    EMZ702

    go.drugbank.com/drugs/DB05021
    Investigational

    EMZ702 has an excellent safety profile and the combination of EMZ702 with interferon and ribavirin in surrogate models for hepatitis C has demonstrated a two to three fold increase in anti-viral potency … EMZ702, a non-toxic agent that has strong anti-viral synergy with interferon, is an ideal candidate for combination with current standard hepatitis C treatments.

  5. Drug

    Leronlimab

    go.drugbank.com/drugs/DB05941
    Investigational

    Leronlimab, or PRO-140, is a human monoclonal antibody developed by CytoDyn.[L12684] It was first described in the literature in 2001. … [A3922] This antibody binds to CCR5, which may be useful in treating HIV, cancers, and severely ill COVID-19 patients.[A192846,A192858,L12684]

  6. Drug

    Olmutinib

    go.drugbank.com/drugs/DB13164
    Investigational

    Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer. … Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016.

    Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
  7. Drug

    Enviomycin

    go.drugbank.com/drugs/DB08993
    Experimental

    It is isolated from an induced mutant of Streptomyces griseoverticillatus var. tuberacticus and acts as an antitubercular agent with less ototoxicity than tuberactinomycin.

  8. Drug

    Senazodan

    go.drugbank.com/drugs/DB19879
    Experimental

    Senazodan is a small molecule drug. The usage of the INN stem '-dan' in the name indicates that Senazodan is a cardiac stimulant, pimobendan derivative.

  9. Drug

    Adibendan

    go.drugbank.com/drugs/DB20623
    Experimental

    Adibendan is a small molecule drug. The usage of the INN stem '-dan' in the name indicates that Adibendan is a cardiac stimulant, pimobendan derivative.

  10. Drug

    Livmoniplimab

    go.drugbank.com/drugs/DB18939
    Investigational

    With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)). … Livmoniplimab is under investigation in clinical trial NCT06109272 (A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination